Pfizer Market Cap 2010-2023 | PFE

Pfizer market cap history and chart from 2010 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of April 22, 2024 is $147.23B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $147.226B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.535B 18.83
Novartis AG (NVS) Switzerland $192.872B 13.86
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67